DexCom (NASDAQ:DXCM) Issues Earnings Results

DexCom (NASDAQ:DXCM) posted its earnings results on Thursday. The medical device company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09, FiscalAI reports. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. During the same period in the previous year, the firm posted $0.48 EPS. The company’s revenue for the quarter was up 13.1% compared to the same quarter last year.

Here are the key takeaways from DexCom’s conference call:

• Positive Sentiment: Dexcom reported Q2 revenue of $1.31 billion, up 13% year over year, with international revenue rising 19%. Management raised full-year revenue guidance to $5.18–$5.25 billion and increased gross and operating margin outlooks.
• Positive Sentiment: The CONNECT trial showed a 1.6% A1C improvement among non-insulin type 2 diabetes patients, with 97% median CGM utilization. Dexcom believes the results could support broader commercial and Medicare reimbursement, including a potential CMS decision by year-end and coverage beginning in mid-2027.
• Positive Sentiment: G7 15-day adoption is tracking to plan, with nearly 50% of the U.S. customer base expected to convert by year-end. The product is now integrated with Tandem systems, has received Canadian regulatory clearance, and is contributing to stronger customer satisfaction and future margin expansion.
• Positive Sentiment: Strong execution drove non-GAAP gross margin to 64.1%, adjusted EBITDA margin to 32.2%, and more than $600 million of free cash flow in the first half. Dexcom repurchased approximately $600 million of stock in Q2 under its $1 billion 2026 authorization and completed its acquisition of Nutrisense to add personalized nutrition insights.
• Neutral Sentiment: Growth initiatives carry some near-term cost and execution considerations, including hiring and startup expenses for the Ireland manufacturing facility and approximately $15 million of second-half international revenue pressure from foreign exchange. Management expects gross margin to dip as Ireland production begins before leveraging over time.

DexCom Trading Down 0.8%

Shares of NASDAQ:DXCM traded down $0.60 during mid-day trading on Thursday, hitting $74.54. The company had a trading volume of 5,620,753 shares, compared to its average volume of 5,218,646. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. DexCom has a one year low of $54.11 and a one year high of $87.00. The firm has a fifty day moving average price of $72.91 and a 200 day moving average price of $69.10. The company has a market capitalization of $28.76 billion, a PE ratio of 31.85, a price-to-earnings-growth ratio of 1.23 and a beta of 1.45.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 analyst consensus, while revenue reached $1.31 billion, ahead of estimates of $1.29 billion. Dexcom Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year revenue forecast raised: Management now expects fiscal 2026 revenue of approximately $5.2 billion to $5.3 billion, compared with consensus around $5.2 billion. The higher outlook reflects strong and sustained demand for continuous glucose monitors. Dexcom raises annual revenue forecast on strong demand for glucose monitors
• Positive Sentiment: Analyst support remains favorable: UBS reaffirmed its “buy” rating and set a $96 price target, implying meaningful upside from recent trading levels. The broader analyst consensus remains “Moderate Buy,” with an average target of $85.40.
• Neutral Sentiment: Valuation and expectations remain important: DXCM trades at roughly 32 times earnings, so continued appreciation may depend on the company sustaining revenue growth and converting strong demand into profit expansion.
• Negative Sentiment: Insider selling may temper sentiment: Former CEO Kevin Sayer sold 26,756 shares worth about $2.04 million. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, reducing its significance as a direct signal about near-term business prospects. DexCom insider transaction filing

Insider Buying and Selling at DexCom

In other DexCom news, insider Kevin R. Sayer sold 26,759 shares of DexCom stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the sale, the insider directly owned 382,482 shares of the company’s stock, valued at approximately $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $74.13, for a total value of $296,520.00. Following the completion of the sale, the director directly owned 52,852 shares of the company’s stock, valued at $3,917,918.76. The trade was a 7.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,506 shares of company stock valued at $7,205,258 over the last 90 days. Insiders own 0.28% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DXCM. DV Equities LLC bought a new stake in shares of DexCom during the fourth quarter worth about $36,000. Aster Capital Management DIFC Ltd bought a new stake in DexCom during the 4th quarter worth approximately $63,000. Quarry LP bought a new stake in DexCom during the third quarter worth $72,000. Summit Securities Group LLC raised its position in DexCom by 817.2% in the 4th quarter. Summit Securities Group LLC now owns 1,174 shares of the medical device company’s stock valued at $78,000 after buying an additional 1,046 shares during the last quarter. Finally, Palisade Asset Management LLC bought a new position in DexCom during the 3rd quarter valued at $81,000. 97.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

DXCM has been the subject of several analyst reports. Citigroup reaffirmed a “buy” rating and set a $84.00 target price (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. Weiss Ratings cut DexCom from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday. Truist Financial raised their price target on shares of DexCom from $80.00 to $87.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a research report on Friday, May 1st. Finally, Mizuho upped their price objective on shares of DexCom from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $85.40.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.